

Mean Change in ADAS-Cog
0
1
2
3
4
5
6
7
8
9
10
3
6
9
12
15
18
Month of Assessment
Placebo
Low Dose

FIG.1



Product-Limit Survival Function Estimates
Low
Placebo
Logrank p=0.1210
Survival Probability
0
0.2
0.4
0.6
0.8
1
0
100
200
300
400
500
Days
No.of Subjects Event Censored Median Survival (95% CL)
Low 30 37%(11) 63%(19) NA (448.0 NA)
Placebo 33 55%(18) 45%(15) 363.0 (264.0 546.0)

FIG.2



15
10
5
0
LSMean Change in ADAS-Cog
8.99
**
5.54
*
6.29
6.92
7.35
10.08
Placebo
0.7-12.8
12.9-21.0
21.6-54.5
54.7-88.3
89.0-197.0
Compound concentration in plasma (ng/mL)
(Quintels cuts)
Placebo
0.7-12.8
12.9-21.0
21.6-54.5
54.7-88.3
89.0-197.0
*p<0.05
**p<0.01

FIG. 3



12
10
8
6
4
2
0
Mean Change in ADAS-Cog
3
6
9
12
15
18
Month of Study
Placebo
Median concentration between 8 and 15

FIG.4



Fit Plot for MEDCONC
MODEL1
NObs 131
NParm 2
EDF 129
MSE 49.474
RSquare 0.1139
AdjRSq 0.107
MEDCONC
40
20
0
-20
20
30
40
50
BMI (kg/m*m)
Fit
95% Prediction Limits
95% Confidence Limits

FIG. 5A



Fit Plot for MEDCONC
MODEL1
NObs 134
NParm 2
EDF 132
MSE 834.19
RSquare 0.077
AdjRSq 0.07
MEDCONC
200
150
100
50
0
20
25
30
35
BMI (kg/m*m)
Fit
95% Prediction Limits
95% Confidence Limits

FIG. 5B



Fit Plot for MEDCONC
MODEL1
NObs 131
NParm 2
EDF 129
MSE 45.123
RSquare 0.1918
AdjRSq 0.1855
MEDCONC
40
30
20
10
0
−10
40
50
60
70
80
90
100
Weight in kg
Fit
95% Prediction Limits
95% Confidence Limits

FIG. 5C



Fit Plot for MEDCONC
MODEL1
NObs 134
NParm 2
EDF 132
MSE 756.55
RSquare 0.1629
AdjRSq 0.1565
MEDCONC
200
150
100
50
0
50
60
70
80
90
100
Weight in kg
Fit
95% Prediction Limits
95% Confidence Limits

FIG. 5D



3 months
6 months
9 months
0
−5
−10
−15
−20
−25
Mean Change from Baseline in Glucose (mg/dL)
Placebo (n=27)
5mg (n=19)
20mg (n=30)

FIG. 6A



3 months
6 months
9 months
0
−5
−10
−15
−20
Mean Change from Baseline in Glucose (mg/dL)
Placebo (n=46)
5mg (n=28)
20mg (n=37)

FIG. 6B



3 months
6 months
9 months
0
−5
−10
−15
−20
−25
Mean Change from Baseline in Glucose (mg/dL)
Placebo (n=36)
5mg (n=22)
20mg (n=32)

FIG. 6C



100
80
60
40
20
0
Mean Glucose (mg/dL)
Baseline
3 months
6 months
9 months
Placebo (n=59)
5mg (n=78)
20mg (n=70)

FIG. 6D



Product-Limit Survival Estimates
With Number of Subjects at Risk
Survival Probability
1.0
0.8
0.6
0.4
0.2
0.0
+ Censored
Low Dose
Placebo
1 135 61 33 22 11 5 4 2 2 1 1
2 131 67 49 41 31 21 19 16 12 6 0
3 132 61 38 29 25 19 16 14 11 9 1
0
200
400
600
Day to First Adverse Event
TRTAN 1: High 2: Low 3: Placebo

FIG. 7



Product-Limit Survival Estimates
With Number of Subjects at Risk
Survival Probability
1.0
0.8
0.6
0.4
0.2
0.0
+ Censored
14.9–31.8ng/mL
0.69–14.6ng/mL
Placebo
1 132 61 38 29 25 19 16 14 11 9 1
2 66 36 27 25 18 11 11 8 7 4 0
3 66 34 24 18 13 10 8 8 5 2 0
4 67 31 15 9 5 2 1 1 1 1 1
5 66 27 16 11 6 3 3 1 1 0
0
200
400
600
Day to First Adverse Event
CRPKI4MAX
1: 0: Placebo
2: 1: 0.69–14.60
3: 2: 14.90–31.80
4: 3: 32.60–75.20
5: 4: 75.70–197.0

FIG. 8